<?xml version="1.0" encoding="UTF-8"?>
<p>In the present hospital-based case-control study, we observed 80 patients with HCC who attended a tertiary care facility from November 2018 to July 2019. This facility is the largest postgraduate public medical university in Bangladesh, located in the capital city, Dhaka, and acts as a reference center for patients having unmanageable diseases. After matching the demographic characteristics of HCC patients, such as age, sex, income, and sociodemographic status, 101 control subjects were chosen. Among the patients visiting public hospitals in Bangladesh, most are the poor and lower-middle-income groups. Hence, we assumed that only this group of people represented the study population in this particular research study. This study was approved by the ethical committee of that particular tertiary hospital and was conducted according to the European Association for the Study of the Liver (EASL) clinical practice guidelines for the management of hepatocellular carcinoma [
 <xref rid="pone.0232121.ref017" ref-type="bibr">17</xref>]. We clarified to the participants the purpose and procedure of the study in detail, their benefits and risks, and subsequently informed consents were obtained from both patients and controls.
</p>
